Background
In 2023, China extended a VAT exemption policy for domestically produced HIV antiretroviral (ARV) drugs under 公告2023年第62号 to support epidemic control efforts. On June 24, 2026, through 公告2026年第18号, 多替拉韦钠 (Dolutegravir Sodium) was added to the list of VAT-exempt ARVs, effective immediately until December 31, 2027. (fgk.chinatax.gov.cn)
Who Benefits
- Manufacturers producing Dolutegravir Sodium no longer need to collect VAT on sales (production and distribution stages)
- Certified procurement agencies under provincial HIV control programs
- Patients who receive these medicines free of charge through public health channels
Requirements and Compliance for Stakeholders
- Drugs must be produced domestically and included in government procurement lists related to HIV treatment agencies. (fgk.chinatax.gov.cn)
- Manufacturers and distributors should separate accounting for exempt vs non-exempt ARV products. Failure to do so could jeopardize the exemption. (guangdong.chinatax.gov.cn)
Practical Impacts
- Cost savings: VAT rate (normally 13%-9% for drugs) is fully exempt for Dolutegravir Sodium—lowers distribution and production cost burdens.
- Patient access: Lower logistical or supply chain tax burdens could improve availability and reduce health system costs.
- Public health outcomes: May support broader HIV treatment coverage, given improved affordability.
Example Case
Manufacturer X produces several HIV-ARV drugs including Dolutegravir Sodium. Under the updated policy, its production cost for this specific product is VAT free. Distributor Y procures it under government procurement and distributes to clinics—none of these stages incur VAT, provided accounting separation is maintained.
Takeaway Points
- Check whether new ARV products are in your invoicing and benefit from the exemption.
- Ensure qualification under government procurement and free provision programs to qualify.
- Keep detailed records: product registration, supply contracts, and separate ledgers for exempt items are essential.
NomadicTax Research Team authored on 2026-08-14